Identify diagnostic criteria for Hypoactive Sexual Desire Disorder (HSDD) and demonstrate the ability to use validated tools like the Decreased Sexual Desire Screener to guide clinical decision-making. |
|
|
|
|
|
|
|
Evaluate candidacy for testosterone therapy in women with HSDD by reviewing baseline labs (including total/free testosterone, sex hormone binding globule) and assessing informed consent for off-label use. |
|
|
|
|
|
|
|
Explain the evidence, risks, and benefits of testosterone therapy in women and design a follow-up plan, including Food and Drug Administration-approved options and monitoring protocols for labs, efficacy, and side effects. |
|
|
|
|
|
|
|
Discuss patient-centered approaches to managing HSDD, incorporating biopsychosocial elements, sexual health counseling, and shared decision-making. |
|
|
|
|
|
|
|
Assess suitability for menopausal hormone therapy (MHT) in women with chronic disease, using a thorough history and risk stratification based on current guidelines. |
|
|
|
|
|
|
|
Discuss the safety profile of MHT in the context of comorbidities, including cardiovascular risk, breast cancer risk, and the role of the timing hypothesis and the type of hormone used (e.g., transdermal vs oral). |
|
|
|
|
|
|
|
Formulate an individualized MHT plan and follow-up protocol, selecting the appropriate estrogen route/dose and progestogen (if uterus is intact), while considering the symptom burden and risk profile. Review optimization and adjustments during therapy. |
|
|
|
|
|
|
|
Recognize the clinical significance of untreated vasomotor symptoms, including the impact on sleep, quality of life, work productivity, and the association between persistent hot flashes and increased risks of cardiovascular disease, bone loss, and cognitive decline |
|
|
|
|
|
|
|